Charge conversional biomimetic nanocomplexes as a multifunctional platform for boosting orthotopic glioblastoma RNAi therapy

Yanjie Liu, Yan Zou, Chan Feng, Albert Lee, Jinlong Yin, Roger Chung, Jong Bea Park, Helen Rizos, Wei Tao, Meng Zheng, Omid C. Farokhzad, Bingyang Shi

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Nanotechnology-based RNA interference (RNAi) has shown great promise in overcoming the limitations of traditional clinical treatments for glioblastoma (GBM). However, because of the complexity of brain physiology, simple blood-brain barrier (BBB) penetration or tumor-targeting strategies cannot entirely meet the demanding requirements of different therapeutic delivery stages. Herein, we developed a charge conversional biomimetic nanoplatform with a three-layer core-shell structure to programmatically overcome persistent obstacles in siRNA delivery to GBM. The resulting nanocomplex presents good biocompatibility, prolonged blood circulation, high BBB transcytosis, effective tumor accumulation, and specific uptake by tumor cells in the brain. Moreover, red blood cell membrane (RBCm) disruption and effective siRNA release can be further triggered elegantly by charge conversion from negative to positive in the endo/lysosome (pH 5.0-6.5) of tumor cells, leading to highly potent target-gene silencing with a strong anti-GBM effect. Our study provides an intelligent biomimetic nanoplatform tailored for systemically siRNA delivery to GBM, leveraging Angiopep-2 peptide-modified, immune-free RBCm and charge conversional components. Improved therapeutic efficacy, higher survival rates, and minimized systemic side effects were achieved in orthotopic U87MG-luc human glioblastoma tumor-bearing nude mice.
Original languageEnglish
Pages (from-to)1637-1646
Number of pages10
JournalNano Letters
Volume20
Issue number3
DOIs
Publication statusPublished - 11 Mar 2020

    Fingerprint

Keywords

  • biomimetic
  • blood−brain barrier
  • charge conversion
  • Glioblastoma
  • siRNA delivery

Cite this